(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 October 2022 (20.10.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/221837 A3

(51) International Patent Classification:
A61K 39/215 (2006.01) *A61P 31/14* (2006.01)
A61K 39/12 (2006.01)

(21) International Application Number:
PCT/US2022/071682

(22) International Filing Date:
12 April 2022 (12.04.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/173,752 12 April 2021 (12.04.2021) US
63/190,199 18 May 2021 (18.05.2021) US

(71) Applicant: **ACADEMIA SINICA** [CN/CN]; 128, Academia Road, Section 2, Nankang, Taipei, 115 (TW).

(72) Inventor; and
(71) Applicant *(for MW only)*: **WONG, Chi-Huey** [US/CN]; 6F, No. 25, Lane 105, Hangzhou South Road, Sec. 1, Zhongzheng Dist., Taipei City, 100 (TW).

(72) Inventors: **MA, Che**; 15F, No. 54 Dongshih Street, Xizhi District, New Taipei City, 22141 (TW). **HUANG, Han-Yi**; 12F., No. 185, Zhongshan Rd., Luzhu Dist., Taoyuan City, 338 (TW).

(74) Agent: **BATHKE, Amy E.**; Prosyla Group PC, 4275 Executive Square, Ste. 200, La Jolla, CA 92037 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) **Title:** IMPROVED CORONAVIRUS VACCINE




Fig. 1

(57) **Abstract:** The present disclosure provides a glycoengineered SARS-CoV-2 spike protein which is capable of eliciting an enhanced immune response relative to a native spike protein of SARS-CoV-2 and its variants. The glycoengineered spike protein exposes the glycosylation sites and at the same time preserves the tertiary structure of the spike protein. The present disclosure therefore provides improved immunogens, vaccines, and methods for better prevention and treatment of the emerging coronavirus infections.

[Continued on next page]

WO 2022/221837 A3

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
24 November 2022 (24.11.2022)